.gif)
Mission Pharmacal Company announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for over-the-counter liquid Potassium Iodide Oral Solution USP. The solution is a ready to use thyroid blocking medication that can be used by all ages in the event of a nuclear emergency.
Potassium iodide works by saturating the thyroid, thereby preventing radioactive iodine from entering the organ. The sooner a person takes potassium iodide following exposure, the more effective the drug will be in preventing thyroid cancer, a leading health concern following nuclear radiation. Infants, children, and pregnant and nursing females are the most vulnerable to radiation poisoning.
Although potassium iodide tablets are available, the FDA recommends a liquid oral solution for infants and small children because it allows for accurate and precise dosing.
"Mission Pharmacal has a long history of dedication to the health and wellbeing of children. We understand the importance of providing a liquid form of potassium iodide that can help protect our nation's most precious resource, our children, who are at greatest risk in the event of a nuclear emergency," says Terry Herring, President of Commercial Operations for Mission Pharmacal. "The FDA's approval of the ANDA for Potassium Iodide Oral Solution is yet another milestone for Mission Pharmacal in our long history and dedication to protecting young lives."
